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Abstract
Objective—To assess the role of sexual relationships on levels and patterns of adherence to 
medication for pre-exposure prophylaxis (PrEP) against HIV.
Methods—We enrolled 1,147 HIV-negative individuals in long-term serodiscordant 
relationships at three sites in Uganda from the Partners PrEP Study- a randomized placebo-
controlled trial of daily oral tenofovir and emtricitabine/tenofovir. We used generalized estimation 
equations to assess the effects of sexual relationships on low adherence (<80%) and on gaps in 
adherence.
Results—Fifty-three percent were male, 51% were 18-34 years and 24% were polygamous. 
Participants who reported sex in the past month with someone other than their primary partner and 
with <100% condom use were more than twice as likely to have low adherence (aOR 2.48, 95% 
CI: 1.70-3.62) compared to those who had sex with only their primary partners and 100% condom 
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use. Using the same reference group, those who abstained from sex in the previous month had 
30% increased odds of low adherence (aOR 1.30, 95% CI: 1.05-1.62), and participants in non-
polygamous marriages who reported sex with both their primary and other partners and <100% 
condom use were almost twice as likely to be low adherers (aOR 1.76, 95% CI: 1.01-3.08). At 
least one 72-hour gap in adherence was seen in 598 participants (54.7%); 23.2% had at least one 
one-week gap.
Conclusions—Risk of low overall adherence was higher in participants who reported sex 
outside primary partnerships and suboptimal condom use, as well as in those who abstained from 
sex. Adherence gaps were common, potentially creating risk for HIV acquisition.
Keywords
HIV pre-exposure prophylaxis; sexual behavior; adherence
Introduction
HIV antiretroviral medications have been shown to reduce the transmission of the virus 
when used for prophylaxis by HIV-negative individuals. 1-3 Based on these studies, the US 
Food and Drug Administration (FDA) approved the use of tenofovir/emtricitabine; an 
antiretroviral drug for pre-exposure prophylaxis (PrEP) by HIV-negative individuals with a 
high risk of acquiring sexually transmitted HIV. 4 PrEP is now one of the few available HIV 
prevention strategies in a field where vaccines and a cure have long been elusive.
Adherence to prescribed antiretroviral medication is known to be vital to successful viral 
suppression and better clinical outcomes in HIV treatment settings. 5 Additionally, 
adherence has been identified to be a key component of effective PrEP. 6 Poor adherence to 
assigned medication is likely the primary reason for the null findings in the FEM-PREP and 
VOICE studies, which assessed the efficacy of oral and topical tenofovir for HIV pre-
exposure prophylaxis among heterosexual African women. 7
Because PrEP is a new tool in HIV prevention, there are limited data on the associations of 
adherence to this medication. However we recently reported that several factors including 
age, heavy alcohol use, being in a polygamous marriage and sexual behavior might affect 
adherence to HIV PrEP. 8 For the purposes of this study polygamy status was defined at 
baseline and referred to one of two situations: 1) an HIV-negative man with more than one 
wife, one of whom was HIV-positive, or 2) an HIV-negative woman whose HIV-infected 
husband had more than one wife. Marriage was be defined by law, religious or local custom. 
We assessed quarterly sexual behavior via interviewer-administered questionnaires and 
quarterly adherence was assessed using the medication event monitoring system (MEMS: 
Aardex, Switzerland). We found that HIV-negative participants who reported sex with only 
people other than their primary sexual partners were twice as likely to have low rates of 
adherence as compared to those who only reported sex with their primary partners (aOR 2.3, 
95% C.I: 1.3 to 3.8). In a second study using SMS surveys for assessing sexual behavior 9, 
participants who did not have sex on a particular day were almost twice as likely to miss a 
dose of PrEP medication on that same day (aOR 1.87, 95% C.I: 1.35 to 2.60).
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To better understand the relationship between sexual behavior and adherence to PrEP, in this 
study, we assessed the associations of sexual behavior with monthly adherence rates, which 
may better assess short-term effects of sexual behavior, as well as with patterns of adherence 
to PrEP. Patterns may be more informative than summary measures of adherence (e.g., 
median values) because lengthy gaps may expose an individual to more risk for HIV 
acquisition compared to occasional missed doses. 10 We also explore the effect condom use 
on adherence within all strata of sexual behavior. We further evaluated the influence of 
polygamy within strata of sexual behavior to explore more closely the role of polygamy on 
adherence to PrEP.
Methods
Study setting and population
We analyzed data from the Partners Ancillary Adherence Study, a sub-study of the Partners 
PrEP Study. 1 The Partners PrEP Study was a multisite, phase III, randomized, double-blind, 
placebo-controlled clinical trial that assessed the efficacy and safety of tenofovir (TDF) and 
emtricitabine/tenofovir (FTC/TDF) for pre-exposure prophylaxis against HIV acquisition. 
This clinical trial enrolled 4758 heterosexual serodiscordant couples at four sites in Kenya 
and five sites in Uganda. Heterosexual couples were defined as “sexual partners of the 
opposite gender who were married, had been living together, or otherwise considered each 
other a primary partner”. The adherence study took place at three of the Ugandan sites 
including Kampala (an urban setting) and Kabwohe and Tororo (rural settings; Figure 1). 
We have previously described details of this study 8, but briefly, we enrolled 1147 HIV-
negative individuals in long-term serodiscordant relationships. All PrEP study participants at 
these sites were eligible for participation as long as they consented for study procedures and 
had at least six or more months of follow-up in the parent clinical trial. Enrollment was 
offered on a rolling basis and all participants provided written informed consent. In addition 
to monthly follow up visits at the clinics, we conducted unannounced home visits for pill 
counts monthly for the first 6 months and then quarterly thereafter. We also used the 
medication event monitoring system [MEMS] to monitor the date and time of pill bottle 
openings. Lastly, participants with <80% monthly adherence to PrEP were started on multi-
session adherence intervention. 11 Data for this analysis was censored at July 10, 2011, the 
date of unbinding of the placebo arm.
Ethical statement
The study was approved by the institutional review boards of participating study sites and 
those of Massachusetts General Hospital/Partners Healthcare and of the University of 
Washington.
Assessment of sexual behavior
Sexual behavior was assessed via interviewer-administered questionnaires completed at 
monthly clinic visits. Face-to-face interviews have not been validated in a PrEP setting but 
have been shown to consistently assess sexual behavior. 12 At each visit, study participants 
met with counselors and discussed several issues relating to HIV-discordancy including 
sexual behavior in the past month. The interviewers queried the number of sexual acts, 
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condom use, and sexual acts with anyone besides the primary partner. Whenever ‘sex’ or 
‘sexual intercourse’ was stated in a question, it included vaginal and anal sex, but not oral 
sex. Interviews were conducted in either English or in a local language of a participant's 
preference and participants were given the option of being interviewed by a counselor of 
their choice.
We categorized monthly sexual behavior as follows: participants who abstained, those who 
had sex with only their primary partners, those who had sex with only other partners (but not 
with their primary partner) and those that had sex with both the primary and other partner(s). 
Each of the above categories was dichotomized into either 100% condom use or <100% 
condom use. The “other partner” category included participants who in the previous month 
did not have sex with their primary partner but reported sex with someone else. We were 
unable to stratify this category by polygamy status at baseline due to small numbers. The 
number of participants was sufficient however to make this stratification for the category 
reporting sex with both the primary and other partner(s).
Assessment of adherence
Monthly adherence to PrEP medication was assessed using the medication event monitoring 
system [MEMS]. This system uses an electronic microchip in the cap of a pill bottle to 
record dates and times the pill bottle was opened and closed. The underlying assumption is 
that every opening and closure of the pill bottle translates to a swallowed dose of the study 
drug. Recorded adherence data was then downloaded during monthly clinic visits. Although 
MEMS is a proxy measure and is subject to misclassification, it allows for assessment of 
adherence patterns by documenting daily pill taking behavior 13 and has been shown to have 
a high positive predictive value of treatment outcomes. 14
We assessed execution of adherence as a dichotomous variable, with 80% or greater 
adherence defined as ‘high adherence’ and < 80% adherence defined as ‘low adherence’. 
The level of adherence required for effective PrEP is not known. However, we recently 
found 100% PrEP efficacy if participants' adherence rates are maintained at 80% and 
above. 8 We also assessed patterns of adherence (i.e., the number of periods of at least 48 
hours, 72 hours and 1 week during with the pill bottle was unopened). We looked at a range 
of patterns because there is limited data on how much tenofovir must be present in blood 
and tissue to offer protection against HIV. Data are also limited on how gaps in adherence 
before and after achievement of stable states affect this protection. Using the heuristic that 
drugs remain in the body for about 4 half-lives 15, it is likely that tenofovir (half life ∼ 17 
hours) is undetectable after a gap of 68 hours, or approximately three days.
Assessments of other covariates
We collected baseline data on the study participant's age, gender, social economic status and 
level of education, all of which have been shown to be associated with adherence in HIV 
treatment settings. 16 We assessed partnership characteristics including how long the couple 
had been living together, the number of children they had, whether one of them was in a 
polygamous marriage and how long they had known that they were HIV discordant. Social 
economic status was assessed using the Filmer-Pritchett index, which uses household items 
Kintu et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
to estimate wealth. 17 For this study, the wealth index for a couple's home reflected the 
presence of a concrete floor, running water, electricity, a television and a house with two or 
more rooms of residence.
Time varying characteristics assessed included heavy alcohol use, depression, number of 
study drug side effects, the participant's perceived risk of HIV acquisition and CD4 cell 
counts of the HIV-infected partner. Depression was assessed using the Hopkins Symptom 
Checklist, a functional impairment assessment instrument that can be used to approximate a 
DSM-IV depression diagnosis, which has been validated in similar populations. 18 Heavy 
alcohol use was assessed using the Rapid Alcohol Problems Screen that has been shown to 
have good sensitivity and specificity in identifying detrimental drinking patterns and has 
cross-nation validity. 19
Statistical analysis
We performed bivariate analyses between each possible covariate and adherence using 
generalized estimating equations (GEE). Monthly adherence execution was modeled using a 
binomial distribution, whereas adherence patterns were modeled with a Poisson distribution. 
For model selection, the initial multivariate model included all variables with a p-value 
≤0.20 from the bivariate analyses. Starting with variables with the highest p-values we 
assessed the scale of maximum likelihood, one at a time and dropped those with p-values 
>0.10 from the final multivariate model. We used a similar method to assess possible 
interaction effects between sexual behaviors with age, gender, study site and social 
economic status, all chosen a priori and used a p-value of <0.10 as a cutoff for statistical 
significance. Data were analyzed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
Results
Study participants
A total of 1,751 HIV-negative participants enrolled in the parent clinical trial at the three 
sites. Of these, 1,182 were offered participation in the adherence study and 1,147 (97%) 
were enrolled. Reasons for not being offered participation included having less than 6 
months remaining for follow-up while on study drug, logistical reasons that would make 
study procedures difficult to conduct and stopping of the parent clinical trial before 
participation could be offered. Thirty-five participants did not meet the criteria for 
enrollment resulting in a final analysis dataset of 1,093 participants (Table 1). Of these, 
53.4% were male, 51.2% were aged between 18 and 34 years, the median number of years 
living with the HIV-positive partner was 8.5 years, and 24.2% were in polygamous 
marriages. The mean follow-up duration was 11 months.
Overall adherence and sexual behavior
A total of 402 (36.7%) participants had at least one month with <80% adherence; this 
translated into 13.3% of the observed months of low adherence. Levels of adherence are 
presented by category of sexual activity and condom use in Table 2. Participants who 
reported sex with other partners only (i.e., no sex with their primary sexual partner) and also 
reported < 100% condom use (N=92) were more than twice as likely to be low adherers as 
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compared to those who had sex only with their primary partners with 100% condom use 
(aOR 2.48, 95% CI: 1.70 to 3.62). The number of other sexual partners had no effect on 
odds for low adherence (OR: 0.98, 95% CI: 0.68-1.40). Using the same reference group, 
those who abstained from sex in the previous month (N=465) had 30% increased odds of 
low adherence (aOR 1.30, 95% CI: 1.05 to 1.62). Participants who reported sex with both 
their primary and other partners (not including polygamous marriages) with < 100% condom 
use (N=60) were almost twice as likely to be low adherers (aOR 1.76, 95% CI: 1.01 to 3.08). 
However, those with similar sexual behavior in the past month but in polygamous marriages 
did not have significantly higher odds of low adherence (aOR: 1.10 95% CI: 0.49 to 2.53).
Participants who reported sex with only their primary partners were more likely to have 
100% condom use as compared to those who had sex with both their primary partners and 
other partner(s), and with those who had sex with only other partners (79%, 33% and 36% 
respectively). Those with low or moderate concern of contracting HIV had 41% lower odds 
of low adherence as compared to those who had no concern of HIV acquisition. Men were 
34% more likely to be low adherers than women. We did not find any significant interaction 
effects of sexual behavior with age (P=0.91), social economic status (P=0.23) or study site 
(P=0.17) on the likelihood of having <80% monthly adherence to PrEP.
Patterns of adherence
Prevalence of gaps in adherence by sexual behavior is presented in Table 3. A total of 598 
(54.7%) of the participants had at least one gap of 72 consecutive hours of non-adherence 
and 254 (23.2%) of these also had at least one one-week gap of non-adherence. Of the 
participants who reported <100% use of condoms in a previous month (N=546), 38.8% had 
at least one 72-hour gap in adherence in that month and 17% had a one-week gap in 
adherence in that month.
Participants who reported sex with other partners only and <100% condom use had 50% 
higher odds of having at least one 72-hour gap in adherence as compared to those who had 
sex with only their primary partners with 100% condom use (aOR 1.50, 95% CI: 1.19 to 
1.91), while those who abstained from sex in the previous month had 17% elevated odds 
(aOR=1.17, 95% CI: 1.01 to 1.35; Table 4). Adherence gaps of 72 hours were not associated 
with reporting sex with both primary and other partners in the previous month, regardless of 
polygamy status. We found similar results when assessing odds of having 48-hour gaps in 
adherence (data not shown). Men were more likely to have had a one-week gap as compared 
to women (aOR: 1.54, 95% CI: 1.04 to 2.27).
Discussion
In this prospective observational study within a randomized clinical trial, HIV-negative 
participants who reported sex with people other than their primary partner and those who 
abstained from sexual activity in the previous month were more likely to be low adherers. 
We found similar, although somewhat weaker associations between sexual activity and gaps 
in adherence. Our findings also indicate that <100% condom use was more common in 
participants who reported sex with only other partners and that participants in polygamous 
marriages did not have increased odds of being low adherers.
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These findings extend results from our previous study. 8 The current study however, 
observed somewhat weaker associations among participants that had abstained in the past 
month, which suggests that the association of abstinence with adherence may be stronger if 
this sexual behavior is sustained over a longer period (in this case, quarterly versus 
monthly). We also found that participants who had sex with only other partners had the 
highest odds of low adherence and having gaps of non-adherence. We are however unable to 
distinguish whether this other partner was a new sexual partner or a partner in a polygamous 
marriage. Nonetheless, these findings indicate that participants who had sex with only other 
partners are more likely to be low adherers. A similar pattern has been observed in some 
HIV treatment settings, where patients with risky sexual behaviors are also more likely to be 
poor adherers to therapy. 20, 21 Also, the highest odds of low adherence were observed in 
participants who had sex with only other partners and in the same month also had less than 
100% condom use. Further research is needed on the dynamics influencing condom use with 
primary partners (HIV-infected) and with other partners. However, one possible explanation 
for both lower adherence and <100% condom use is low perceived risk of acquiring HIV 
from the other partner.
To our knowledge no study has explicitly assessed the role of polygamy on adherence. 
Several studies have however found that polygamy offers a protective effect against HIV-
acquisition. 22, 23 Our previous findings showed that participants in polygamous marriage 
had a 60% reduced odds for low adherence as compared to those from monogamous 
marriages. 8 We did not find a protective effect in this study but did find no increased risk 
among polygamous partners. We hypothesize that HIV-negative partners in discordant and 
polygamous marriages receive extra social support to adhere to PrEP so as to prevent 
transmission of HIV within the polygamous marriage. This concept is consistent with our 
recent findings that spousal support plays a key role in PrEP adherence. 24 The lack of a 
protective effect in our study could be multifactorial. First, we had small numbers of people 
in these stratifications. Secondly, the one-month exposure period might not be long enough 
to assess the protective effect that was observed in quarterly assessment of sexual behavior 
on adherence.
This is the first study to assess the effect of sexual behavior on patterns of adherence. 
Though previous studies have shown that participants in Partners PrEP Study had high rates 
of adherence 8, we found that many participants had gaps of not taking their medication. 
Such intermittent dosing is likely to increase the risk of acquiring HIV since every 
subsequent day of non-adherence results in a lower concentration of active drug. This 
increased risk is consistent with findings from the FEM-PrEP study that showed high rates 
of inconsistent use of the study drug that could have contributed to the lack of a protective 
effect in the active study arms. 25 Some of the observed gaps, however, could have been due 
to pocket doses (i.e., removal of multiple tablets with one opening for later use) —a well-
established limitation of electronic adherence measurement, and may not reveal true gaps in 
adherence. The correlation of adherence gaps with other potentially risky sexual behaviors, 
like sex with other partners, suggests that many are real. Additionally, we do not know if 
these gaps in adherence were covered by other forms of HIV prevention (e.g., condoms). 
This highlights the need for a better understanding of the use of combination prevention 
strategies. Additionally, among participants who reported abstinence in the previous month, 
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some extended gaps could have could been intentional because of no perceived risk of HIV 
transmission in that period. Such practices may be logical; however, the correlation of 
specific dosing patterns with achievement and maintenance of drug levels sufficient for 
providing effective protection against HIV infection are unknown. Such an understanding 
will be crucial in advising individuals on how to start and stop PrEP (i.e., periodic dosing) 
with the confidence that it will be effective. These findings can be used in designing HIV 
prevention programs with a PrEP component. For example, PrEP might not be the 
recommended HIV prevention method for people who know that they will not be having sex 
for certain periods. Also, individuals with outside partners may benefit from additional 
counseling on risk perception and strategies for including PrEP when they are with these 
other partners.
Our study's strengths include the use of a prospective study design to assess the effects of 
short-term sexual behaviors on low adherence. Our large sample size enabled us to assess 
the effects of many aspects of sexual behavior. One study limitation was that few 
participants reported sexual activity with both their primary and other partners. We therefore 
had limited statistical power to assess associations between sexual behavior and adherence 
within some strata of sexual behavior. Also, we did not have data on relationship discord, a 
risk factor that has been suggested to be critical to adherence to PrEP medication 26 and 
were therefore unable to evaluate possible confounding by this factor. Also, data on sexual 
behavior were collected using self-report which is subject to social desirability bias, which 
may result in to less reporting of some risky sexual behaviors. Lastly, we could not 
distinguish if other partners were actually within polygamous marriages.
In conclusion, our findings identify groups of people in HIV serodiscordant relationships 
who may require extra adherence support during PrEP implementation programs-- namely, 
those with multiple partners but are not in polygamous marriages. In addition, PrEP eligible 
persons who are likely to abstain from sex may need prevention methods that are more 
suitable to intermittent need. Also, we found that though overall adherence rates were high, 
many participants missed taking their study pills for relatively long periods of time, 
potentially creating risk for HIV acquisition. Further research is needed on the use and 
efficacy of intermittent and periodic PrEP from trials and demonstration projects. We also 
found that polygamy might be a factor influencing better adherence due to the desire to 
prevent HIV transmission within a polygamous marriage. However, more work is needed to 
ascertain this effect using a study with more people that report this behavior and one that 
distinguishes whether or not the “other partner” is part of the polygamous marriage.
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Figure 1. Study populations for the Partners PrEP Study and the Ancillary Adherence Study
1Two sites were in a rural settings and the third was in an urban setting.
2Reasons for not being enrolled included participant decline, not meeting inclusion criteria 
and not being offered participation into the study (after stopping of the parent clinical trial 
by the DSMB)
3Fiftyfour participants excluded due of censoring the analysis dataset to before July 10 2011
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Table 1
Baseline characteristics of study participants (N=1093)
Characteristic N %
Male (N, %) 584 53.4
Age (N, %)
 18-24 86 7.9
 25-34 475 43.5
 35-44 392 35.9
 44+ 140 12.8
Education level (N, %)
 Primary or less (≤ 7 years) 821 75.1
 Secondary (8-13 years) 244 22.3
Post secondary (> 13 years) 28 2.6
Primary source of income (N, %)
 Professional 66 6.0
 Laborer 220 20.1
 Trade/sales 148 13.5
 Farming 635 58.1
 Other 24 2.2
On placebo (N, %) 387 35.4
Duration of knowledge of discordance, years (median, range) 1 0-14
Number of years living together (median, range) 8.5 0-39
Polygamous marriage (N, %)1 264 24.2
Number of children in partnership (median, range) 2 0-13
CD4 cell count in HIV-infected partner, cells/mm3 (N, %)2
< 200 30 2.8
 200-350 246 22.5
> 350 817 74.7
1
Referred to one of two situations: 1) an HIV-negative man with more than one wife, one of whom was HIV-positive, or 2) an HIV-negative 
woman whose HIV-infected husband had more than one wife
2
Assessed at beginning of adherence study
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